Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm
Authors:
- Suparna C. ClasenSCSuparna C. Clasen
- Rupal O’qUinnRORupal O’qUinn
- 1 December 2017
- journal article
- research article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 8 (6) , 970-979
Abstract
Background: Fluoropyrimidine chemotherapy [5-fluorouracil (5-FU) and capecitabine] are commonly used agents in the treatment of various solid malignancies. However, their use has been limited by cardiac toxicity, presenting as a wide spectrum of asymptomatic (e.g., EKG changes) and symptomatic (e.g., chest pain) manifestations related to coronary vasospasm leading to myocardial ischemia. Historically, patients with suspected coronary vasospasm have been treated with traditional acute ischemic workup and various combinations of anti-anginal therapies. In addition, most patients typically are not rechallenged with fluoropyrimidine after experiencing initial cardiovascular side-effects with resulting interruption of planned chemotherapy regimens. Methods: We report a case series of 11 consecutive patients in a single-center with suspected fluoropyrimidine-induced coronary vasospasm who were successfully rechallenged with the culprit drug to allow for planned chemotherapy completion. Our protocol utilized rechallenge with bolus infusional regimen of intravenous fluoropyrimidine chemotherapy and oral capecitabine with cardioprotective pretreatment with two calcium blockers and long-acting oral nitrate therapy. Results: We were successfully able to continue and complete the previously planned first-line chemotherapy regimen for all 11 patients with minimal therapeutic interruption. There have been no cardiac events or evidence of recurrent coronary spasm after completion of therapy with discontinuation of prophylactic medications upon therapy completion. Conclusions: We report a single-institution experience of successful rechallenge with fluoropyrimidines with careful cardiac monitoring and the combined use of calcium channel blockers and long-acting nitrates. With further study, this algorithm can be used to safely continue fluoropyrimidines, a potentially curative regimen in the treatment of many solid tumors.Keywords
This publication has 31 references indexed in Scilit:
- Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced CardiotoxicityClinical Colorectal Cancer, 2013
- 5-fluorouracil induced cardiotoxicity: Review of the literatureCardiology Journal, 2012
- 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicityCancer Chemotherapy and Pharmacology, 2011
- Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.2009
- 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levelsMedical Oncology, 2009
- Cardiotoxicity of 5-FluorouracilCardiovascular & Hematological Agents in Medicinal Chemistry, 2006
- Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-upJapanese Journal of Clinical Oncology, 2005
- Vascular events in patients receiving high‐dose infusional 5‐fluorouracil‐based chemotherapy: The University of Chicago experienceMedical and Pediatric Oncology, 1991
- Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.Journal of Clinical Oncology, 1989
- Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patientsCancer Chemotherapy and Pharmacology, 1982